help button home button Am J Pathol R & D Systems
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Order Full text via Infotrieve
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Garnier, J. L.
Right arrow Articles by Cannon, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garnier, J. L.
Right arrow Articles by Cannon, M. J.

American Journal of Pathology, Vol 142, 353-358, Copyright © 1993 by American Society for Investigative Pathology

REGULAR ARTICLES

Low expression of CD20 and CD23 in Epstein-Barr virus-induced B cell tumors in SCID/hu mice

JL Garnier, NR Cooper and MJ Cannon
Department of Immunology, Scripps Research Institute, La Jolla, California 92037.

Intraperitoneal injection of immunodeficient C.B.-17/scid (SCID) mice with human peripheral blood leukocytes from Epstein-Barr virus (EBV)- seropositive donors or with peripheral blood leukocytes from EBV- seronegative donors followed by an injection of EBV results in the development of human B-cell tumors. EBV-induced oligoclonal SCID/hu tumors closely resemble the EBV-associated lymphoproliferative disorders that are complications in immunosuppressed transplant patients. Previous reports have indicated that SCID/hu tumor cells are phenotypically similar to in vitro-transformed lymphoblastoid cell lines (LCL), which express high levels of mature B-cell lineage/activation antigens (CD19, CD20, CD21, CD23, CD30, CD39). In this study, however, flow cytometric (FACS) analysis showed that expression of CD20 and CD23 by SCID/hu tumor cells was markedly reduced relative to CD20 and CD23 expression by donor-matched, in vitro- transformed LCL. Injection of LCL into SCID mice also produced tumors in which CD20 and CD23 expression was greatly reduced relative to levels expressed by the injected LCL. In addition, tumorigenesis following LCL injection was associated with the production of high levels of human Ig in the sera of SCID mice. Our data thus indicate that EBV-driven tumorigenesis in vivo is associated with significant changes in B-cell phenotype relative to EBV-infected B cells transformed in vitro.


This article has been cited by other articles:


Home page
 J. Virol.Home page
M. Islas-Ohlmayer, A. Padgett-Thomas, R. Domiati-Saad, M. W. Melkus, P. D. Cravens, M. d. P. Martin, G. Netto, and J. V. Garcia
Experimental Infection of NOD/SCID Mice Reconstituted with Human CD34+ Cells with Epstein-Barr Virus
J. Virol., December 15, 2004; 78(24): 13891 - 13900.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Khanolkar, Z. Fu, L. J. Underwood, K. L. Bondurant, R. Rochford, and M. J. Cannon
CD4+ T Cell-Induced Differentiation of EBV-Transformed Lymphoblastoid Cells Is Associated with Diminished Recognition by EBV-Specific CD8+ Cytotoxic T Cells
J. Immunol., March 15, 2003; 170(6): 3187 - 3194.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by the American Society for Investigative Pathology.